Work

FcyRIIB Is a Novel Immune Checkpoint in the Tumor Microenvironment Limiting Activity of Treg-Targeting Antibodies

Year: 2023

Type: preprint

Source: bioRxiv (Cold Spring Harbor Laboratory)

DOI: 10.1101/2023.01.19.522856

Authors: David Knorr, Rom Leidner, Shawn Jensen, Ryan Meng, Andrew Jones, Carmen Ballesteros-Merino, R. Bryan Bell, Maria Baez, David Sprott, Carlo Bifulco, Brian Piening, Rony Dahan, Bernard A. Fox, Jeffrey Ravetch

Institutions: Memorial Sloan Kettering Cancer Center, Rockefeller University, Providence Portland Medical Center, Weizmann Institute of Science

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: M.J. Murdock Charitable Trust, Bristol-Myers Squibb, National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences

Awards: Fc-enhanced CD40 agonist antibodies for immune modulation of the tumor microenvironment, SPORE in Bladder Cancer, G361980993, Immunologic Approaches to Ovarian Cancer, Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics, Cancer Center Support Grant, Institutional Career Development Core, Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success, Molecular mechanisms of antibody-mediated immunotherapies

OpenAlex ID: W4317569132

Cites: 24

Cited by: 3

Related to: 10